Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin vs nitroglycerin for reducing bleeding during hepatectomy
ChiCTR2000039142Phase 4Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of terlipressin in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA) and liver cancer (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Intraoperative blood loss. Started Nov 2020; status: recruiting.
02
Drugs
terlipressin
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)liver cancer
Beyond the preview
Go deeper on ChiCTR2000039142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039142.